Best Practices and Emerging Evidence in the Treatment of Atopic Dermatitis in Children and Adolescents

Atopic dermatitis, a chronic and relapsing inflammatory skin condition, affects up to 20% of children in the United States, burdening young patients with symptoms like itching, pain, and disrupted sleep. These challenges can take a toll on quality of life—but the landscape of treatment is evolving rapidly.

In this engaging course, Dr. Peter A. Lio, Clinical Assistant Professor of Dermatology & Pediatrics at Northwestern University Feinberg School of Medicine, and Dr. Linda F. Stein Gold, Director of Dermatology Clinical Research and Division Head of Dermatology at Henry Ford Health, explore the latest advancements in pediatric atopic dermatitis care. Discover best practices and cutting-edge research that can help optimize outcomes for children and adolescents living with atopic dermatitis. Start the activity now!

STATEMENT OF NEED

Atopic dermatitis is a chronic, relapsing, inflammatory skin disease that impacts up to 20% of children in the United States (Silverberg et al, 2021). Children with atopic dermatitis experience a high symptom burden, including pruritus, pain, and sleep disturbances, which significantly impact quality of life. Recently, the therapeutic landscape for atopic dermatitis has expanded  to include several new options for children (Chu et al, 2024; Davis et al, 2024). Nonsteroidal topicals, topical and oral JAK inhibitors, and anti–IL-4 receptor alpha and anti–IL-13 monoclonal antibodies, are now available to patients. Others, including therapies targeting the OX40 pathway, are under late-stage investigation (Tsuji et al, 2023). As new therapies emerge, it is crucial for members of the interdisciplinary care team to learn about these options that can optimize outcomes for patients. In this activity, Dr. Peter A. Lio, Clinical Assistant Professor of Dermatology & Pediatrics at Northwestern University Feinberg School of Medicine, and Dr. Linda F. Stein Gold, Director of Dermatology Clinical Research and Division Head of Dermatology at Henry Ford Health, provide insights into best practices and emerging evidence in the treatment of atopic dermatitis in children and adolescents.

TARGET AUDIENCE

Dermatologists, pediatricians, family medicine physicians, nurse practitioners, physician assistants/associates, nurses, and other healthcare providers involved in the treatment of patients with atopic dermatitis (AD).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to

• Appraise clinical features that can inform the differential diagnosis of AD in children and adolescents 
• Evaluate the efficacy and safety of novel and emerging therapies for AD in children and adolescents

REGISTRATION

There is no fee to participate in or claim CME/NCPD credit for this activity.

PROVIDED BY

JOINTLY ACCREDITED PROVIDER

In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS

i3 Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants/Associates

i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 12/19/25. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioners

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Nursing Continuing Professional Development

A maximum of 0.75 ANCC contact hours may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.75 ANCC contact hours of pharmacology credit for Advanced Practice Registered Nurses.

Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 0.75 ANCC contact hours. 

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/NCPD activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD activity. CME/NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME/NCPD content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Peter A. Lio, MD, discloses that he has served on a speaker's bureau for AbbVie, Arcutis, Eli Lilly, Galderma, Hyphens Pharma, Incyte, La Roche-Posay/L'Oreal, MyOR Diagnostics, Pfizer, Pierre-Fabre Dermatologie, Regeneron/Sanofi Genzyme, and Verrica; that he has served on an advisory board or panel for AbbVie, Alphyn Biologics, Almirall, Amyris, Arcutis, Bristol Myers Squibb, Codex Labs, Concerto Biosci, Dermavant, Eli Lilly, Galderma, Hyphens Pharma, Incyte, Janssen, La Roche-Posay/L'Oreal, LEO Pharma, Micreos, MyOR Diagnostics, Pathos Therapeutics, Pfizer, Pierre-Fabre Dermatologie, Regeneron/Sanofi Genzye, Skinfix, Soteri Skin, Suneco Technologies, UCB, Verdant Scientific, Verrica, and Yobee Care; that he is a stock/shareholder with Alphyn Biologics, Codex Labs, Concerto Biosci, Soteri Skin, Suneco Technologies, Verdant Scientific, and Yobee Care; and that he has received other financial or material support (royalties, patents, etc.) from Theraplex.

Linda F. Stein Gold, MD, discloses that she has served on a speaker's bureau for AbbVie, Amgen, Arcutis, Dermavant, Incyte, Leo, Lilly, Pfizer, Regeneron, and Sanofi; that she has served on an advisory board or panel for AbbVie, Amgen, Arcutis, Dermavant, Incyte, Leo, Lilly, Pfizer, Regeneron, and Sanofi; that she has served as a consultant for AbbVie, Amgen, Arcutis, Dermavant, Incyte, Leo, Lilly, Pfizer, Regeneron, and Sanofi; and that she has received grants/research support from AbbVie, Amgen, Arcutis, Dermavant, Incyte, Leo, Lilly, Pfizer, Regeneron, and Sanofi.

i3 Health has mitigated all relevant financial relationships.

COMMERCIAL SUPPORT

This activity is supported by educational funding provided by Amgen.